Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years

Health Canada approved pembrolizumab in the first-line setting for advanced non-small-cell lung cancer with PD-L1 ≥ 50% and no EGFR/ALK aberration. The keynote 024 trial showed 55% of such patients progress with pembrolizumab monotherapy. We propose that the combination of baseline CT and clinical f...

Descripción completa

Detalles Bibliográficos
Autores principales: Silver, Ali, Ho, Cheryl, Ye, Qian, Zhang, Jianjun, Janzen, Ian, Li, Jessica, Martin, Montgomery, Wu, Lang, Wang, Ying, Lam, Stephen, MacAulay, Calum, Melosky, Barbara, Yuan, Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297400/
https://www.ncbi.nlm.nih.gov/pubmed/37366902
http://dx.doi.org/10.3390/curroncol30060419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297400/
https://www.ncbi.nlm.nih.gov/pubmed/37366902
http://dx.doi.org/10.3390/curroncol30060419

Ejemplares similares